Answer
Yes, Jakavi (ruxolitinib phosphate) has been associated with increased total, HDL and LDL cholesterol and triglycerides; lipid monitoring and treatment of dyslipidaemia according to clinical guidelines are recommended.
Sources for this answer
- Jakavi 5mg, 10mg, 15mg and 20mg TabletsNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 29Document updated
Sources checked